Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Hepatitis

Free Subscription Articles published in Hepatology Retrieve available abstracts of 161 articles: HTML format

Single Articles

May 2026
1. GERUSSI A, Sebode M, Nofit E, Stoelinga A, et al
   Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus.
   Hepatology. 2026 May 14. doi: 10.1097/HEP.0000000000001793.
   PubMed     Abstract available
   
   
   
2. KAMAL H, Jargalsaikhan G, Enkhtaivan S, Lindahl K, et al
   Diabetes, male sex, low levels of HBsAg, HDV RNA and ALT predict spontaneous HDV suppression in chronic hepatitis D.
   Hepatology. 2026 May 12. doi: 10.1097/HEP.0000000000001786.
   PubMed     Abstract available
   
   
   
3. CARI V, Perez MI, Tellez I, Idalsoaga F, et al
   Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study.
   Hepatology. 2026 May 6. doi: 10.1097/HEP.0000000000001780.
   PubMed     Abstract available
   
   
   April 2026
4. BEHRENDT P, Neumann-Haefelin C
   Two decades of Hepatitis E in solid organ transplantation: From endemic insight to unresolved therapeutic questions.
   Hepatology. 2026 Apr 14. doi: 10.1097/HEP.0000000000001769.
   PubMed    
   
   
   
5. YANHANG G, Xinrui W, Zhongfeng W, Fei K, et al
   A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B.
   Hepatology. 2026 Apr 6. doi: 10.1097/HEP.0000000000001754.
   PubMed     Abstract available
   
   
   
6. KAMAR N, Abravanel F, Marion O, Couat C, et al
   Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis.
   Hepatology. 2026 Apr 3. doi: 10.1097/HEP.0000000000001762.
   PubMed     Abstract available
   
   
   
7. PUTIGNANO A, Kelkar NS, Lakhloufi D, Sharma S, et al
   Antibody response to microbiota antigens is associated with alcohol-related liver disease severity and predicts mortality.
   Hepatology. 2026;83:838-850.
   PubMed     Abstract available
   
   
   March 2026
8. TORNAI D, Mitchell MC, McClain CJ, Dasarathy S, et al
   Longitudinal assessment of circulating cytokine profile of severe alcohol-associated hepatitis.
   Hepatology. 2026 Mar 13. doi: 10.1097/HEP.0000000000001743.
   PubMed     Abstract available
   
   
   
9. RAHMAN SA, Gangadhara S, Gridley J, Mala U, et al
   T and B cell targeting DNA/MVA HCV vaccines induce strong and broad cellular and humoral immunity in mice and rhesus macaques.
   Hepatology. 2026 Mar 6. doi: 10.1097/HEP.0000000000001732.
   PubMed     Abstract available
   
   
   February 2026
10. LUCIFORA J, Negro F
    Shedding new light on the chicken-and-egg dilemma of hepatitis delta virus (HDV) replication initiation.
    Hepatology. 2026 Feb 13. doi: 10.1097/HEP.0000000000001705.
    PubMed    
    
    
    
11. PRAWIRA A, Hilleke M, Chen M, Roninson IB, et al
    CDK8 and CDK19 Mediator kinases are required for hepatitis delta virus replication.
    Hepatology. 2026 Feb 10. doi: 10.1097/HEP.0000000000001690.
    PubMed     Abstract available
    
    
    January 2026
12. GOMEZ-ESCOBAR E, Flores N, Shoukry NH
    Erratum: One step closer to a pan-genotypic hepatitis C vaccine.
    Hepatology. 2026;83:E72.
    PubMed    
    
    
    November 2025
13. STRAIN R, Edmans M, Montalvo Zurbia-Flores G, Frumento N, et al
    The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.
    Hepatology. 2025 Nov 14. doi: 10.1097/HEP.0000000000001599.
    PubMed     Abstract available
    
    
    
14. GHANY MG, Pan CQ, Lok AS, Feld JJ, et al
    AASLD/IDSA Practice Guideline on treatment of chronic hepatitis B.
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001549.
    PubMed     Abstract available
    
    
    
15. PAN CQ, Saadi S, Ghany MG, Feld JJ, et al
    Technical systematic review supporting 2025 AASLD Practice Guidelines on management of chronic hepatitis B.
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001584.
    PubMed     Abstract available
    
    
    
16. THOMPSON AJ, Cornberg M
    Commentary - AASLD Practice Guideline on treatment of chronic hepatitis B (2025 Update).
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001582.
    PubMed    
    
    
    
17. 
    Updated AASLD Guidelines for Chronic Hepatitis B Treatment.
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001607.
    PubMed    
    
    
    
18. SIDHU G
    When "remission" isn't enough: The unseen burden of autoimmune hepatitis.
    Hepatology. 2025;82:1037-1038.
    PubMed    
    
    
    
19. DANPANICHKUL P, Duangsonk K, Chen VL, Saokhieo P, et al
    Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021.
    Hepatology. 2025;82:1274-1286.
    PubMed     Abstract available
    
    
    October 2025
20. ZOU Y, Li Q
    Letter to the Editor: Rethinking prognostic endpoints in alcohol-associated hepatitis.
    Hepatology. 2025 Oct 13. doi: 10.1097/HEP.0000000000001571.
    PubMed    
    
    
    
21. WANG Y, Lu C, Ding L, Lv Q, et al
    To the editor: Clarifying LSM cutoff validation, statistical power, and subgroup applicability in predicting liver-related events in chronic hepatitis B.
    Hepatology. 2025 Oct 7. doi: 10.1097/HEP.0000000000001558.
    PubMed    
    
    
    
22. SUN Y, Chen S, Zhao X, You H, et al
    Reply: Clarifying LSM cutoff validation, statistical power, and subgroup applicability in predicting liver- related events in chronic hepatitis B.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001559.
    PubMed    
    
    
    September 2025
23. SANDULESCU O, Dudman SG, Gmizic I, Garcia F, et al
    Global Hepatitis C elimination: Updates, challenges, and opportunities from real-world experiences in Europe and North America.
    Hepatology. 2025 Sep 26. doi: 10.1097/HEP.0000000000001548.
    PubMed    
    
    
    
24. GOMEZ-ESCOBAR E, Flores N, Shoukry NH
    One step closer to a pan-genotypic hepatitis C vaccine.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001530.
    PubMed    
    
    
    
25. ZHANG F, Zhao Y, Bian L, Wang X, et al
    IL1beta Signaling Mediates the Interaction Between Hepatitis B and C Viruses.
    Hepatology. 2025 Sep 12. doi: 10.1097/HEP.0000000000001525.
    PubMed     Abstract available
    
    
    
26. DASARATHY S, Tu W, Welch N, Gawrieh S, et al
    Natural history and development of a novel composite endpoint in patients with alcohol-associated Hepatitis: Data from a prospective multicenter study.
    Hepatology. 2025 Sep 9. doi: 10.1097/HEP.0000000000001513.
    PubMed     Abstract available
    
    
    
27. URBANEK-QUAING M, Chou YH, Gupta MK, Steppich K, et al
    Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition.
    Hepatology. 2025;82:739-754.
    PubMed     Abstract available
    
    
    August 2025
28. GAO P, Ge W, Wang R
    Letter to the editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis.
    Hepatology. 2025 Aug 4. doi: 10.1097/HEP.0000000000001485.
    PubMed    
    
    
    July 2025
29. CHOI WM, Seto WK
    Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis.
    Hepatology. 2025 Jul 15. doi: 10.1097/HEP.0000000000001469.
    PubMed    
    
    
    June 2025
30. LI J, Xu L, Rui F, Tran S, et al
    Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naive chronic hepatitis B patients with concurrent hepatic steatosis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001442.
    PubMed     Abstract available
    
    
    
31. GOMEZ-MORENO A, Bradley D, Ploss A
    Building hepatitis B virus gene transcription from the bottom up.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001437.
    PubMed    
    
    
    
32. WANG H, Wang S, Lei Y, Chen Y, et al
    Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001419.
    PubMed     Abstract available
    
    
    
33. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
    Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2025;81:E181.
    PubMed    
    
    
    
34. OZMERT EH
    Infliximab to the rescue: Autoimmune hepatitis meets its match.
    Hepatology. 2025;81:1621-1622.
    PubMed    
    
    
    May 2025
35. KILANY MM, Sonneveld MJ, Feld JJ, Janssen HLA, et al
    Management of Immune Tolerant Chronic Hepatitis B.
    Hepatology. 2025 May 20. doi: 10.1097/HEP.0000000000001407.
    PubMed     Abstract available
    
    
    April 2025
36. WANG J, Zhang S, Fan T, Wu C, et al
    Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001365.
    PubMed    
    
    
    
37. TSENG TC, Kao JH
    Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001366.
    PubMed    
    
    
    
38. HUI VW, Wong GL, Dai J, Tse YK, et al
    Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001354.
    PubMed     Abstract available
    
    
    
39. TSENG TC, Lok AS
    Accurate identification and risk-stratification of HBeAg-negative indeterminate phase of chronic hepatitis B: not all shades of grey are the same.
    Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001353.
    PubMed    
    
    
    
40. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326.
    PubMed    
    
    
    March 2025
41. GRONBAEK L, Vilstrup H, Jepsen P
    Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325.
    PubMed    
    
    
    
42. SU R, Tao X, Yan L, Liu Y, et al
    Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
    PubMed     Abstract available
    
    
    
43. TSENG TC, Hosaka T, Pan MH, Liu CJ, et al
    Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients.
    Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001313.
    PubMed     Abstract available
    
    
    
44. ZHANG T, Huang CJ, Chen HT, Huang YH, et al
    HLA-DQB1*03:01 and risk of Hepatitis B virus-related hepatocellular carcinoma.
    Hepatology. 2025 Mar 14. doi: 10.1097/HEP.0000000000001307.
    PubMed     Abstract available
    
    
    February 2025
45. SNIJDERS RJALM, Janik MK, Mund M, Uhlenbusch N, et al
    Health-related quality of life is impaired in people with autoimmune hepatitis: Results of a multicentre cross-sectional study within the European Reference Network.
    Hepatology. 2025 Feb 19. doi: 10.1097/HEP.0000000000001271.
    PubMed     Abstract available
    
    
    
46. WONG GL, Chan HL
    Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.
    Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273.
    PubMed    
    
    
    
47. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2025;81:609-624.
    PubMed     Abstract available
    
    
    
48. WEDEMEYER H, Leus M, Battersby TR, Glenn J, et al
    HDV RNA assays: Performance characteristics, clinical utility, and challenges.
    Hepatology. 2025;81:637-650.
    PubMed     Abstract available
    
    
    January 2025
49. YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
    Prevalence and predictors of cirrhosis and portal hypertension in the united states.
    Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
    PubMed     Abstract available
    
    
    
50. SHI MA, Pungwe P, Comer LL, Balakrishnan M, et al
    Corticosteroids in severe alcohol-associated hepatitis? Not so fast: A systematic review of randomized controlled trials.
    Hepatology. 2025 Jan 28. doi: 10.1097/HEP.0000000000001237.
    PubMed     Abstract available
    
    
    
51. CHEN PC, Deterding K, Engelskircher SA, Port K, et al
    TIGIT-expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.
    Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001238.
    PubMed     Abstract available
    
    
    
52. NISHITSUJI H, Naito Y, Murakami Y, Sugiyama M, et al
    Identification of glycogen synthase kinase 3alpha/beta as a host factor required for hepatitis B virus transcription using high-throughput screening.
    Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239.
    PubMed     Abstract available
    
    
    
53. PATEL K, Asrani SK, Fiel MI, Levine D, et al
    Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2025;81:358-379.
    PubMed     Abstract available
    
    
    December 2024
54. CHEN KQ, Chen Y, Peng JF, Tang WR, et al
    Letter to the Editor: Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001210.
    PubMed    
    
    
    
55. BERETTA M, Vesin B, Wei Y, Planchais C, et al
    Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection.
    Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001179.
    PubMed     Abstract available
    
    
    
56. MULLISH BH, Thursz MR
    Alcohol-associated liver disease: Emerging therapeutic strategies.
    Hepatology. 2024;80:1372-1389.
    PubMed     Abstract available
    
    
    November 2024
57. JOHN BV, Bastaich D, Dahman B
    Reply: Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001162.
    PubMed    
    
    
    
58. HE Z, Wang C, Tian H
    Letter to the editor : Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001159.
    PubMed    
    
    
    
59. 
    Erratum: Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose.
    Hepatology. 2024;80:E90.
    PubMed    
    
    
    
60. 
    Erratum: JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralization.
    Hepatology. 2024;80:E86.
    PubMed    
    
    
    
61. CHUNG Y, IIkay E, Heneghan MA
    Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol.
    Hepatology. 2024;80:1000-1002.
    PubMed    
    
    
    
62. KEZER CA
    The ultimate ensemble: Seeing the forest through the trees in alcohol-associated hepatitis.
    Hepatology. 2024;80:995-996.
    PubMed    
    
    
    
63. MALHI G, Arab JP
    Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol.
    Hepatology. 2024;80:989-990.
    PubMed    
    
    
    October 2024
64. JOHN BV, Bastaich D, Dahman B
    Reply: Association of hepatitis D virus infection with liver-related outcomes.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001142.
    PubMed    
    
    
    
65. LUO C
    Letter to the Editor: Association of hepatitis D virus infection with liver-related outcomes.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001140.
    PubMed    
    
    
    
66. WRANKE A, Wedemeyer H
    Hepatitis D virus - still the devil !
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001144.
    PubMed    
    
    
    
67. COLPITTS CC, Baumert TF
    Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions.
    Hepatology. 2024 Oct 22. doi: 10.1097/HEP.0000000000001132.
    PubMed    
    
    
    
68. OLESEN CH, Collignon L, Velazquez-Moctezuma R, Fanalista M, et al
    Prevalence of hepatitis C virus hypervariable region 1 insertions and their role in antibody evasion.
    Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001114.
    PubMed     Abstract available
    
    
    
69. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Reply: The causal analysis of missing confounding factors for the association between HDV and specific liver events.
    Hepatology. 2024;80:E50-E52.
    PubMed    
    
    
    
70. LI Z, Zhang Y, Li Y, Lan J, et al
    Letter to the Editor: The causal analysis of missing confounding factors for the association between HDV and specific liver events.
    Hepatology. 2024;80:E48-E49.
    PubMed    
    
    
    
71. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
    Role of microbiome in autoimmune liver diseases.
    Hepatology. 2024;80:965-987.
    PubMed     Abstract available
    
    
    September 2024
72. HSU CL, Wang L, Maestri E, Jacob AR, et al
    Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.
    Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001046.
    PubMed     Abstract available
    
    
    
73. SONG M, Wang H, Tian X, Gao J, et al
    TIPE2 protein restrains invariant NKT activation and protects against immune-mediated hepatitis in mice.
    Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001104.
    PubMed     Abstract available
    
    
    
74. LIAW YF, Papatheodoridis G
    Finite nucleos(t)ide-analogue therapy for functional cure in HBeAg-negative chronic hepatitis B: recent development in the paradigm shift.
    Hepatology. 2024 Sep 24. doi: 10.1097/HEP.0000000000001107.
    PubMed     Abstract available
    
    
    
75. ZHU J, Wu R, Yang T, Yuan Y, et al
    Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release storm by targeting translation machinery.
    Hepatology. 2024 Sep 20. doi: 10.1097/HEP.0000000000001101.
    PubMed     Abstract available
    
    
    
76. LYU X, Sze KM, Lee JM, Husain A, et al
    Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications.
    Hepatology. 2024 Sep 13. doi: 10.1097/HEP.0000000000001087.
    PubMed     Abstract available
    
    
    
77. JOHN BV, Bastaich D, Amoli MM, Wong RJ, et al
    Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001092.
    PubMed     Abstract available
    
    
    
78. EFE C, Lytvyak E, Eskazan T, Liberal R, et al
    Efficacy and safety of infliximab in patients with autoimmune hepatitis.
    Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001089.
    PubMed     Abstract available
    
    
    
79. SUN B, da Costa KAS, Alrubayyi A, Kokici J, et al
    HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses.
    Hepatology. 2024;80:649-663.
    PubMed     Abstract available
    
    
    
80. LI Z, Zhang Y, Li Y, Chen X, et al
    Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
    Hepatology. 2024;80:E37-E38.
    PubMed    
    
    
    
81. HUANG DQ, Nguyen MH
    Reply: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
    Hepatology. 2024;80:E39.
    PubMed    
    
    
    August 2024
82. ABRAVANEL F, Vignon C, Mercier A, Gaumery JB, et al
    Large-scale hepatitis E virus genotype 3 outbreak on new caledonia island.
    Hepatology. 2024 Aug 30. doi: 10.1097/HEP.0000000000001081.
    PubMed     Abstract available
    
    
    
83. MCGETTIGAN BM, Osna N
    Functional humoral immunity is crucial to outcomes in severe alcohol-associated hepatitis.
    Hepatology. 2024 Aug 27. doi: 10.1097/HEP.0000000000001079.
    PubMed    
    
    
    
84. KHANAM A, Kottilil S
    Reversal of immune exhaustion for functional cure of chronic hepatitis B: Is the time right?
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001059.
    PubMed    
    
    
    
85. VAN DER MEER AJ, Sonneveld MJ
    Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
    PubMed    
    
    
    
86. STAFYLIS C, Vij AP, Klausner JD
    Letter to the editor: Bridging the gap between hepatitis C virus diagnosis and treatment to achieve elimination in the united states.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001051.
    PubMed    
    
    
    
87. GRATACOS-GINES J, Ventura-Cots M, Pose E
    Reply: Don't forget to discuss TIPS in patients surviving an episode of alcoholic hepatitis.
    Hepatology. 2024 Aug 2. doi: 10.1097/HEP.0000000000001040.
    PubMed    
    
    
    July 2024
88. RUDLER M, Bouzbib C, Thabut D
    To the Editor: Don't forget to discuss TIPS in patients surviving an episode of alcoholic hepatitis.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001038.
    PubMed    
    
    
    
89. YUAN Q, Hodgkinson C, Liu X, Barton B, et al
    Exome-wide association analysis identifies novel risk loci for alcohol-associated hepatitis.
    Hepatology. 2024 Jul 26. doi: 10.1097/HEP.0000000000001027.
    PubMed     Abstract available
    
    
    
90. PATIDAR KR, Tu W, Cotter TG, Simonetto DA, et al
    Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone.
    Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001019.
    PubMed     Abstract available
    
    
    
91. QIAN J, Xie Y, Mao Q, Xie Q, et al
    A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally-suppressed, HBeAg negative chronic hepatitis B patients.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001006.
    PubMed     Abstract available
    
    
    
92. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001005.
    PubMed     Abstract available
    
    
    
93. 
    Erratum: The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
    Hepatology. 2024;80:E22.
    PubMed    
    
    
    
94. 
    Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    PubMed    
    
    
    June 2024
95. LAW JL, Drummer HE
    Bridging the gap: A new tool to down select HCV vaccine candidates.
    Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000000948.
    PubMed    
    
    
    
96. LI J, Ma X, Xuan Q, Li Q, et al
    Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
    PubMed     Abstract available
    
    
    
97. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
    Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
    PubMed    
    
    
    
98. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    PubMed    
    
    
    
99. BITTERMANN T, Yagan L, Kathawate RG, Weinberg EM, et al
    Real-world evidence for factors associated with maintenance treatment practices among U.S. adults with autoimmune hepatitis.
    Hepatology. 2024 Jun 12. doi: 10.1097/HEP.0000000000000961.
    PubMed     Abstract available
    
    
    
100. TANG T, Li LQ, Wang ZD
     Baseline viral load in chronic hepatitis B may be clinically significant but must be interpreted with caution.
     Hepatology. 2024 Jun 6. doi: 10.1097/HEP.0000000000000956.
     PubMed    
     
     
     
101. CORNBERG M, Wedemeyer H
     Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination!
     Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958.
     PubMed    
     
     
     
102. HOWELL J, Hellard ME
     Reply: Provider preparedness for functional cure of chronic hepatitis B.
     Hepatology. 2024;79:E160.
     PubMed    
     
     
     May 2024
103. WELTZSCH JP, Bartel CF, Waldmann M, Renne T, et al
     Optimizing thiopurine therapy in autoimmune hepatitis: A multi-center study on monitoring metabolite profiles and co-therapy with allopurinol.
     Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000940.
     PubMed     Abstract available
     
     
     
104. LIAO X, Fan R
     Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
     Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000942.
     PubMed    
     
     
     
105. FENG Z
     Cathepsins prime hepatitis E virus for cell entry.
     Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000936.
     PubMed    
     
     
     
106. POL S, Thompson AJ, Collins M, Venier E, et al
     Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
     Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
     PubMed     Abstract available
     
     
     
107. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
     The obstacle is the way: Finding a path to hepatitis C elimination.
     Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
     PubMed    
     
     
     
108. LUO C
     Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
     Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000928.
     PubMed    
     
     
     
109. KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al
     Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune mediated liver injury.
     Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926.
     PubMed     Abstract available
     
     
     
110. HALL EW, Bradley H, Barker LK, Lewis K, et al
     Estimating hepatitis C prevalence in the United States, 2017-2020.
     Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
     PubMed     Abstract available
     
     
     
111. KLOHN M, Burkard T, Janzen J, Haase JA, et al
     Targeting cellular cathepsins inhibits hepatitis E virus entry.
     Hepatology. 2024 May 10. doi: 10.1097/HEP.0000000000000912.
     PubMed     Abstract available
     
     
     
112. SHENOY A, Fontana RJ
     HDV screening in chronic HBV: An unmet need of growing importance.
     Hepatology. 2024;79:979-982.
     PubMed    
     
     
     
113. SEMMLER G, Mandorfer M
     The fade-out of HCV coinfection of people who live with HIV.
     Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
     PubMed    
     
     
     April 2024
114. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
     JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
     Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
     PubMed     Abstract available
     
     
     
115. ZAHOOR MA, Feld JB, Lin HS, Mosa AI, et al
     Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN trials.
     Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000878.
     PubMed     Abstract available
     
     
     
116. DUNN W, Li Y, Singal AK, Simonetto DA, et al
     An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study.
     Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000883.
     PubMed     Abstract available
     
     
     
117. CHOI WM, Lim YS
     "Reply: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients".
     Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000884.
     PubMed    
     
     
     
118. HE T, Zhang D
     Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
     Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000882.
     PubMed    
     
     
     March 2024
119. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
     NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
     Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
     PubMed     Abstract available
     
     
     
120. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
     Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
     Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
     PubMed     Abstract available
     
     
     
121. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
     Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
     Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
     PubMed     Abstract available
     
     
     
122. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
     Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
     Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
     PubMed     Abstract available
     
     
     
123. PERRILLO RP, Janssen HLA
     Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis B.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000810.
     PubMed    
     
     
     
124. KONDILI LA, Craxi A
     Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
     PubMed    
     
     
     
125. GRATACOS-GINES J, Ruz-Zafra P, Celada-Sendino M, Marti-Carretero A, et al
     Recurrent alcohol-associated hepatitis is common and is associated with increased mortality.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000825.
     PubMed     Abstract available
     
     
     February 2024
126. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
     Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
     PubMed     Abstract available
     
     
     
127. YAMAZAKI T, Kouno T, Hsu CL, Hartmann P, et al
     Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000777.
     PubMed     Abstract available
     
     
     
128. PAPATHERODORIDIS G, Lampertico P
     Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
     Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
     PubMed    
     
     
     
129. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
     Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
     PubMed    
     
     
     
130. YU H, Shin EC
     Duet of humoral and cellular immunity for conquering hepatitis C virus.
     Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
     PubMed    
     
     
     
131. DIMOU A, Zachou K, Kostara C, Azariadis K, et al
     NMR-based metabolomic signature: An important tool for the diagnosis and to study pathogenesis of autoimmune hepatitis.
     Hepatology. 2024 Feb 5. doi: 10.1097/HEP.0000000000000767.
     PubMed     Abstract available
     
     
     January 2024
132. CHOI WM, Yip TC, Kim WR, Yee LJ, et al
     Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000752.
     PubMed     Abstract available
     
     
     
133. 
     Erratum: Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
     Hepatology. 2024 Jan 19. doi: 10.1097/HEP.0000000000000759.
     PubMed    
     
     
     
134. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
     Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
     Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
     PubMed     Abstract available
     
     
     
135. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
     Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
     Hepatology. 2024;79:183-197.
     PubMed     Abstract available
     
     
     December 2023
136. KINAST V, Todt D
     The relation of host genetics and symptomatic hepatitis E.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000749.
     PubMed    
     
     
     
137. JENG WJ, Chien RN, Liaw YF
     Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
     PubMed    
     
     
     
138. CHEN J, Tu T, Cohen C, Wang S, et al
     Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
     PubMed    
     
     
     
139. YIP TC, Brunetto MR
     Hepatitis B surface antigen seroclearance is uncommon but durable in the long run.
     Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000741.
     PubMed    
     
     
     
140. SAADAT A, Gouttenoire J, Ripellino P, Semela D, et al
     Inborn errors of type I interferon immunity in patients with symptomatic acute hepatitis E.
     Hepatology. 2023 Dec 8. doi: 10.1097/HEP.0000000000000701.
     PubMed     Abstract available
     
     
     November 2023
141. SHEN J, Zhang K, Liu M, Wang T, et al
     Letter to the Editor: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
     Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000682.
     PubMed    
     
     
     
142. LEE J, Gil D, Park H, Lee Y, et al
     A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
     PubMed     Abstract available
     
     
     
143. GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al
     Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687.
     PubMed     Abstract available
     
     
     
144. HE S, Peng Y, Wei Q
     Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
     PubMed    
     
     
     
145. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
     Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
     PubMed    
     
     
     
146. DE CARVALHO RIBEIRO M, Babuta M, Szabo G
     Reply: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000686.
     PubMed    
     
     
     
147. BRUDEN D, McMahon BJ, Snowball M, Towshend-Bulson L, et al
     Rate and durability of clearance of hepatitis B surface antigen in Alaska Native persons with long-term hepatitis B virus infection: 1982-2019.
     Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000658.
     PubMed     Abstract available
     
     
     
148. LEE CH, Mak LY, Tang EH, Lui DT, et al
     SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
     Hepatology. 2023;78:1569-1580.
     PubMed     Abstract available
     
     
     October 2023
149. JENG WJ, Chien RN, Liaw YF
     Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
     PubMed    
     
     
     
150. DENG R, Wang Z, Liu Y, Sun J, et al
     Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
     PubMed    
     
     
     
151. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
     Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
     PubMed     Abstract available
     
     
     
152. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
     Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
     PubMed    
     
     
     
153. LIAW YF, Jeng WJ, Chien RN
     Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
     PubMed    
     
     
     
154. ELSHEIKH R, Makram AM, Huy NT
     Reply: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
     Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000625.
     PubMed    
     
     
     
155. JAGADISAN B, Dhawan A
     Letter to the Editor: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
     Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000622.
     PubMed    
     
     
     September 2023
156. CHOLANKERIL G, Vierling JM
     The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis: Close is not good enough!
     Hepatology. 2023 Sep 18. doi: 10.1097/HEP.0000000000000597.
     PubMed    
     
     
     
157. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
     Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
     Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
     PubMed     Abstract available
     
     
     
158. GILL US, Peppa D
     Pegylated interferon-alpha for chronic hepatitis B...not ready to be shelved yet! new insights on its role using single-cell transcriptomics.
     Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000560.
     PubMed     Abstract available
     
     
     May 2023
159. TONON M, Balcar L, Semmler G, Calvino V, et al
     Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
     Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
     PubMed     Abstract available
     
     
     April 2023
160. KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
     Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
     Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
     PubMed     Abstract available
     
     
     January 2023
161. CUNNINGHAM M, Gupta R, Butler M
     Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum